Official Journal of the Human Genome Organisation
Table 1 Comparing clinical profile of patients among the four treatment groups (Mean ± SD)
From: High dose Losartan and ACE gene polymorphism in IgA nephritis
ARB (200 mg) n = 63 | ARB (100 mg) n = 43 | ACEI (20 mg) n = 61 | ACEI (10 mg) n = 40 | P value* | |
|---|---|---|---|---|---|
Sex (F:M) | 34:29 | 18:25 | 26:35 | 19:21 | NS |
Age at biopsy (years) | 34 ± 10 | 32 ± 12 | 32 ± 10 | 34 ± 11 | NS |
Duration of trial (months) | 75 ± 3 | 74 ± 3 | 74 ± 2 | 75 ± 2 | NS |
Hypertension (yes:no) | 33:30 | 20:23 | 33:29 | 18:22 | NS |
EGFR (ml/min) | |||||
Before | 63.5 ± 24.2 | 61.2 ± 18.4 | 62.2 ± 20.8 | 60.9 ± 19.8 | NS |
After | 59.1 ± 31.8 | 40.2 ± 27.6 | 41.3 ± 27.9 | 42.3 ± 26.6 | P = 0.0005* |
(P = 0.009) | (P < 0.001) | (P < 0.001) | (P < 0.001) | ||
Decrease in eGFR (ml min−1year−1) | 0.7 ± 3.1 | 3.4 ± 3.2 | 3.5 ± 3.3 | 3.2 ± 2.6 | P = 0.0005* |
Urinary protein (g/day) | |||||
Before | 2.2 ± 0.9 | 2.0 ± 1.0 | 2.2 ± 1.6 | 2.3 ± 1.5 | NS |
After | 1.2 ± 0.8 | 1.6 ± 0.9 | 1.7 ± 1.0 | 1.7 ± 0.9 | P = 0.0005* |
(P < 0.001) | (P = 0.053) | (P = 0.004) | (P = 0.009) | ||
Blood pressure (mmHg) | |||||
Systolic before | 132 ± 12 | 132 ± 12 | 134 ± 11 | 132 ± 12 | NS |
Systolic after | 128 ± 11 | 128 ± 11 | 129 ± 10 | 130 ± 10 | NS |
(P < 0.001) | (P < 0.001) | (P < 0.001) | (P < 0.002) | ||
Diastolic before | 84 ± 7 | 85 ± 7 | 83 ± 7 | 86 ± 5 | NS |
Diastolic after | 83 ± 6 | 84 ± 6 | 83 ± 8 | 84 ± 7 | NS |
NS | NS | NS | NS | ||
Outcome | |||||
Non-ESRF | 56 | 33 | 42 | 31 | NS |
ESRF | 7 | 10 | 19 | 9 | |
Improvement in eGFR | |||||
Yes | 23 | 8 | 6 | 3 | χ2 = 19.8 |
No | 40 | 35 | 55 | 37 | (P < 0.001) |